BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For example, in CML using a CRISPR/Cas9-mediated knockout approach, the loss of PTPRC significantly improved response to both imatinib and nilotinib, first and second-generation BCR-ABL TKIs, respectively (40).